Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Olanzapin (ausschl. Dafo. TRS), ATC N05AH03 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Mon)

Section 130a, paragraph 8, of the SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For the pharmaceuticals to be specified by the bidder in Annex 2 to the contract for the aforementioned substance Olanzapin (exclusively TRS dosage form), ATC N05AH03, DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the approval model for the aforementioned substance comes into force for the first time on 01.09.2026 and ends on 31.08.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.